congenital factor x deficiency is a rare autosomal recessive bleeding disorder that presents with variable bleeding tendency and prolonged coagulation tests, prothrombin time, and partial thromboplastin time. thromboembolic events have not been reported in patients with factor x deficiency yet. herein, we report a patient with factor x deficiency who had recurrent venous thromboembolic events.

Thromboembolic disorders are among the major causes of morbidity and mortality, and anticoagulation remains the cornerstone of prevention and treatment of these disorders. Although effective, the well-established agents have significant drawbacks. Heparin, low molecular weight heparin, and fondaparinux must be given parenterally, which is inconvenient for long-term or home use. The orally admin...

Venous thromboembolic disorders (VTE) are serious disorders with high morbidity and mortality rates. Many genetic and acquired risk factors were identified to cause VTE. The most common genetic risk factor is Factor V Leiden mutation (FVL). FVL was found in high percentage of populations of Caucasian origin but was almost absent in non-Caucasians. It was also reported in populations living in N...

Left ventricular non-compaction (LVNC) is a rare disease that can occur isolated or in association with other disorders, including congenital heart disease and musculoskeletal disorders. It is characterized by a two-layered myocardium with excessive trabeculation of the left ventricle. Diagnosis is challenging as left ventricular trabeculations can be pathological yet can also be a normal findi...

drug utilization evaluation (due) is an effective program to identify variability in drug use and to support interventions that will improve patient outcomes. the appropriate use of enoxaparin, a low molecular weight heparin (lmwh), which is widely used as curative or preventive treatment of thromboembolic disorders was assessed in the study. a prospective due was carried out at masih daneshvar...

Heparins and vitamin K antagonists have been the cornerstones of anticoagulation therapy for several decades. Although they are very effective at inhibiting the coagulation process, they have several practical limitations. This was a challenge for the development of therapies that will overcome these drawbacks while matching the efficacy of the two classes of anticoagulants. Advances were achie...

D uring the last 20 yrs, a tremendous amount of scientific discoveries have greatly improved our knowledge on the pathophysiology of pulmonary hypertension, and expanded our armamentarium of important novel medications that have substantially improved survival and the quality of life of patients suffering from this devastating disorder. Although most investigations have focused on pulmonary art...

Pulmonary hypertension (PH) is often difficult to diagnose and many different disorders may result in elevated pulmonary arterial pressure requiring therapy. Left untreated, PH usually has a dismal prognosis culminating in right ventricular failure and death. Besides conservative therapeutic strategies such as anticoagulation and diuretics, the past decade has brought remarkable improvements in...